It's been a good week for BioNTech SE (NASDAQ:BNTX) shareholders, because the company has just released its latest quarterly results, and the shares gained 3.6% to US$111. Despite revenues of €261m falling 6.0% short of expectations, statutory losses of €1.60 per share were well contained, and in line with analyst models. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

After the latest results, the consensus from BioNTech's 19 analysts is for revenues of €2.29b in 2025, which would reflect a painful 20% decline in revenue compared to the last year of performance. Per-share losses are expected to explode, reaching €3.94 per share. Before this latest report, the consensus had been expecting revenues of €2.25b and €3.67 per share in losses. Overall it looks as though the analysts were a bit mixed on the latest consensus updates. Although revenue forecasts held steady, the consensus also made a modest increase to its losses per share forecasts.

View our latest analysis for BioNTech

The consensus price target held steady at US$137, seemingly implying that the higher forecast losses are not expected to have a long term impact on the company's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic BioNTech analyst has a price target of US$171 per share, while the most pessimistic values it at US$112. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

Of course, another way to look at these forecasts is to place them into context against the industry itself. Over the past five years, revenues have declined around 9.7% annually. Worse, forecasts are essentially predicting the decline to accelerate, with the estimate for an annualised 37% decline in revenue until the end of 2025. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 19% per year. So while a broad number of companies are forecast to grow, unfortunately BioNTech is expected to see its revenue affected worse than other companies in the industry.

The Bottom Line

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at BioNTech. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that BioNTech's revenue is expected to perform worse than the wider industry. The consensus price target held steady at US$137, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on BioNTech. Long-term earnings power is much more important than next year's profits. We have forecasts for BioNTech going out to 2027, and you can see them free on our platform here.

We also provide an overview of the BioNTech Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.